In a report issued on June 23, Ed Arce from H.C. Wainwright maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), with a price target of $45.00. The company’s shares closed last Friday at $8.18, close to its 52-week low of $3.97.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.2% and a 37.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $35.00, representing a 317.7% upside. In a report issued on June 13, RBC Capital also reiterated a Buy rating on the stock with a $35.00 price target.
Based on Pliant Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.25 million and GAAP net loss of $28.1 million. In comparison, last year the company earned revenue of $2.17 million and had a GAAP net loss of $22.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Read More on PLRX:
- Rite Aid Stock: Some Good News, Lots of Bad News
- Intellia Therapeutics (NTLA) Gets a Buy Rating from Brookline Capital Markets
- JPMorgan Chase & Co. (JPM) Gets a Sell Rating from Morgan Stanley
- BlackBerry Stock: Bulls Can Cherry-Pick Outstanding Data Points
- CarMax Stock: A Promising Vehicle for Potential Upside